- Cosmo Pharmaceuticals announces that Cosmo Intelligent Medical Devices – IMD Ltd, fully owned subsidiary of Cosmo Pharmaceuticals, and Medtronic to expand cooperation on GI Genius™
- Cosmo Pharmaceuticals reports record results for 2022, preliminary results exceeding guidance, increased dividend distribution and 2023 guidance
As of last trade
Cosmo Pharmaceuticals NV (C43X:GER) traded at 56.00, -20.00% below its 52-week high of 70.00, set on Feb 16, 2023.
41.60Jun 15 202270.00Feb 16 2023
Short selling activityProvided by S&P Global Market Intelligence
|Market cap||949.88m CHF|
|EPS (TTM)||1.87 |
|Annual div (ADY)||0.95 |
|Annual div yield (ADY)||1.71%|
|Div ex-date||Jun 01 2022|
|Div pay-date||Jun 03 2022|
Data delayed at least 15 minutes, as of Mar 22 2023 08:51 BST.